Protalix BioTherapeutics (PLX) Change in Accured Expenses (2010 - 2026)
Protalix BioTherapeutics' quarterly Change in Accured Expenses came in at $820000.0 in Q1 2026, up 163.86% year-on-year from $310767.4 in Q1 2025, and down 81.04% quarter-over-quarter from $4.3 million in Q4 2025.
Protalix BioTherapeutics has reported Change in Accured Expenses for 17 years, with the latest figure at $820000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses rose 163.86% year-over-year to $820000.0; the trailing twelve-month figure through Mar 2026 stood at $2.4 million (up 190.07% YoY), and the FY2025 full-year result was $292000.0, down 58.05% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at $820000.0, down from $4.3 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $4.3 million in Q4 2025, with the low at -$3.9 million in Q2 2022.
- Average Change in Accured Expenses over 5 years is $135235.3, with a median of $177000.0 recorded in 2023.
- Year-over-year, Change in Accured Expenses jumped 503.01% in 2023 and plunged 590.96% in 2024.
- Tracing PLX's Change in Accured Expenses over 5 years: stood at -$366000.0 in 2022, then jumped by 503.01% to $1.5 million in 2023, then retreated by 7.39% to $1.4 million in 2024, then soared by 216.62% to $4.3 million in 2025, then tumbled by 81.04% to $820000.0 in 2026.
- The last three Change in Accured Expenses figures came in at $820000.0 (Q1 2026), $4.3 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 820,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 820,000.00 |
| Mar 31, 2026 | 820,000.00 |
| Dec 31, 2025 | 4.33 Mn |
| Dec 31, 2025 | 4.33 Mn |
| Sep 30, 2025 | -2.14 Mn |
| Sep 30, 2025 | -2.14 Mn |
| Jun 30, 2025 | -610,000.00 |
| Jun 30, 2025 | -610,000.00 |
| Mar 31, 2025 | -1.28 Mn |
| Mar 31, 2025 | -1.28 Mn |
| Dec 31, 2024 | 1.37 Mn |
| Dec 31, 2024 | 1.37 Mn |
| Sep 30, 2024 | -869,000.00 |
| Sep 30, 2024 | -869,000.00 |
| Jun 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | 1.61 Mn |
| Mar 31, 2024 | -1.41 Mn |
| Mar 31, 2024 | -1.41 Mn |
| Dec 31, 2023 | 1.48 Mn |
| Dec 31, 2023 | 1.48 Mn |
| Sep 30, 2023 | 177,000.00 |
| Sep 30, 2023 | 177,000.00 |
| Jun 30, 2023 | 3.29 Mn |
| Jun 30, 2023 | 3.29 Mn |
| Mar 31, 2023 | 353,000.00 |
| Mar 31, 2023 | 353,000.00 |
| Dec 31, 2022 | -366,000.00 |
| Dec 31, 2022 | -366,000.00 |
| Sep 30, 2022 | 426,000.00 |
| Sep 30, 2022 | 426,000.00 |
| Jun 30, 2022 | -3.85 Mn |
| Jun 30, 2022 | -3.85 Mn |
| Mar 31, 2022 | -1.01 Mn |
| Mar 31, 2022 | -1.01 Mn |
| Dec 31, 2021 | 1.32 Mn |
| Dec 31, 2021 | 1.32 Mn |
| Sep 30, 2021 | 1.61 Mn |
| Sep 30, 2021 | 1.61 Mn |
| Jun 30, 2021 | -1.12 Mn |
| Jun 30, 2021 | -1.12 Mn |
| Mar 31, 2021 | 575,000.00 |
| Mar 31, 2021 | 575,000.00 |
| Dec 31, 2020 | -1.02 Mn |
| Dec 31, 2020 | -1.02 Mn |
| Sep 30, 2020 | 2.98 Mn |
| Sep 30, 2020 | 2.98 Mn |
| Jun 30, 2020 | -2.30 Mn |
| Jun 30, 2020 | -2.30 Mn |
| Mar 31, 2020 | 2.61 Mn |
| Mar 31, 2020 | 2.61 Mn |
| Dec 31, 2019 | -2.17 Mn |
| Dec 31, 2019 | -2.17 Mn |
| Sep 30, 2019 | 3.43 Mn |
| Sep 30, 2019 | 3.43 Mn |
| Jun 30, 2019 | 607,000.00 |
| Jun 30, 2019 | 607,000.00 |
| Mar 31, 2019 | 864,000.00 |
| Mar 31, 2019 | 864,000.00 |
| Dec 31, 2018 | 1.04 Mn |
| Dec 31, 2018 | 1.04 Mn |
| Sep 30, 2018 | -517,000.00 |
| Sep 30, 2018 | -517,000.00 |
| Jun 30, 2018 | -279,000.00 |
| Jun 30, 2018 | -279,000.00 |
| Mar 31, 2018 | -1.01 Mn |
| Mar 31, 2018 | -1.01 Mn |
| Dec 31, 2017 | -3.80 Mn |
| Dec 31, 2017 | -3.80 Mn |
| Sep 30, 2017 | 3.32 Mn |
| Sep 30, 2017 | 3.32 Mn |
| Jun 30, 2017 | 3.01 Mn |
| Jun 30, 2017 | 3.01 Mn |
| Mar 31, 2017 | 2.37 Mn |
| Mar 31, 2017 | 2.37 Mn |
| Dec 31, 2016 | 1.77 Mn |
| Dec 31, 2016 | 1.77 Mn |
| Sep 30, 2016 | -906,000.00 |
| Sep 30, 2016 | -906,000.00 |
| Jun 30, 2016 | 1.74 Mn |
| Jun 30, 2016 | 1.74 Mn |
| Mar 31, 2016 | -470,000.00 |
| Mar 31, 2016 | -470,000.00 |
| Dec 31, 2015 | -384,000.00 |
| Dec 31, 2015 | -384,000.00 |
| Sep 30, 2015 | -849,000.00 |
| Sep 30, 2015 | -849,000.00 |
| Jun 30, 2015 | -168,000.00 |
| Jun 30, 2015 | -168,000.00 |
| Mar 31, 2015 | -472,000.00 |
| Mar 31, 2015 | -472,000.00 |
| Mar 31, 2014 | -450,000.00 |
| Mar 31, 2014 | -450,000.00 |
| Dec 31, 2013 | 6.28 Mn |
| Dec 31, 2013 | 6.28 Mn |
| Sep 30, 2013 | -2.37 Mn |
| Sep 30, 2013 | -2.37 Mn |
| Jun 30, 2013 | -43,000.00 |
| Jun 30, 2013 | -43,000.00 |
| Mar 31, 2013 | -3.01 Mn |
| Mar 31, 2013 | -3.01 Mn |
| Dec 31, 2012 | 2.61 Mn |
| Dec 31, 2012 | 2.61 Mn |
| Sep 30, 2012 | -1.76 Mn |
| Sep 30, 2012 | -1.76 Mn |
| Jun 30, 2012 | 2.37 Mn |
| Jun 30, 2012 | 2.37 Mn |
| Mar 31, 2012 | -242,000.00 |
| Mar 31, 2012 | -242,000.00 |
| Dec 31, 2011 | 1.76 Mn |
| Dec 31, 2011 | 1.76 Mn |
| Sep 30, 2011 | -382,000.00 |
| Sep 30, 2011 | -382,000.00 |
| Jun 30, 2011 | 2.21 Mn |
| Jun 30, 2011 | 2.21 Mn |
| Mar 31, 2011 | 2.56 Mn |
| Mar 31, 2011 | 2.56 Mn |
| Dec 31, 2010 | -3.16 Mn |
| Dec 31, 2010 | -3.16 Mn |
| Sep 30, 2010 | 3.14 Mn |
| Sep 30, 2010 | 3.14 Mn |